New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
06:17 EDTICPTIntercept initiated with a Neutral at Goldman
Goldman Sachs started shares of Intercept with a Neutral rating saying it's difficult to value the company's obeticholic acid for the treatment of nonalcoholic steatohepatitis without the FLINT trial data, which is due out later this year. Goldman put a $265 price target on the stock.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ICPT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use